BiotechTube

Sitexsentin sodium + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diastolic Heart Failure

Conditions

Diastolic Heart Failure

Trial Timeline

Mar 27, 2006 → May 1, 2008

NCT ID
NCT00303498

About Sitexsentin sodium + Placebo

Sitexsentin sodium + Placebo is a phase 2 stage product being developed by Pfizer for Diastolic Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT00303498. Target conditions include Diastolic Heart Failure.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00303498Phase 2Completed

Competing Products

6 competing products in Diastolic Heart Failure

See all competitors
ProductCompanyStageHype Score
regadenosonAstellas PharmaApproved
85
Dapagliflozin + PlaceboAstraZenecaPhase 2
52
ValsartanNovartisApproved
85
valsartanNovartisApproved
85
RanolazineGilead SciencesPhase 2
51
Sildenafil + PlaceboPfizerPhase 3
76

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84